Trial · NCT00300430
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study | ABT-335 + 20 mg Rosuvastatin | -53.0 | Full Range 27.67 | percent change | |
| Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Simvastatin | -47.7 | Full Range 24.62 | percent change | |
| Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Atorvastatin | -56.2 | Full Range 24.56 | percent change | |
| Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 20 mg Rosuvastatin | 25.2 | Standard Deviation 23.22 | percent change | |
| Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Simvastatin | 25.1 | Standard Deviation 25.08 | percent change | |
| Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Atorvastatin | 19.4 | Standard Deviation 20.58 | percent change | |
| Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 20 mg Rosuvastatin | -41.6 | Standard Deviation 20.77 | percent change | |
| Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Simvastatin | -30.2 | Standard Deviation 21.83 | percent change | |
| Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Atorvastatin | -38.1 | Standard Deviation 19.09 | percent change | |
| Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study | ABT-335 + 20 mg Rosuvastatin | -48.8 | Standard Deviation 15.80 | percent change | |
| Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study | ABT-335 + 40 mg Simvastatin | -36.6 | Standard Deviation 16.90 | percent change | |
| Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study | ABT-335 + 40 mg Atorvastatin | -44.3 | Standard Deviation 15.72 | percent change | |
| Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 20 mg Rosuvastatin | -56.9 | Standard Deviation 27.85 | percent change | |
| Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Simvastatin | -37.7 | Standard Deviation 63.12 | percent change | |
| Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Atorvastatin | -52.2 | Standard Deviation 36.54 | percent change | |
| Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study | ABT-335 + 20 mg Rosuvastatin | -37.9 | Standard Deviation 13.14 | percent change | |
| Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Simvastatin | -27.5 | Standard Deviation 14.60 | percent change | |
| Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Atorvastatin | -35.0 | Standard Deviation 13.01 | percent change | |
| Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study | ABT-335 + 20 mg Rosuvastatin | -44.8 | Standard Deviation 15.40 | percent change | |
| Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study | ABT-335 + 40 mg Simvastatin | -35.5 | Standard Deviation 14.85 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00300430/results